A new clinical trial, known as the AERIFY-2 study, is underway in Mooresville, N.C., focusing on chronic obstructive pulmonary disease (COPD). Conducted by Sanofi, this study is investigating itepekimab’s potential to diminish the frequency and severity of COPD exacerbations in both current and former smokers with moderate-to-severe COPD.
COPD is a major health concern and the sixth leading cause of death in the United States. Patients with COPD often suffer from exacerbations, which are periods when their respiratory symptoms intensify and become more difficult to manage than usual. These exacerbations can be severe enough to necessitate hospitalization and are associated with an elevated risk of mortality. Though there are treatments available for COPD, there is an urgent need for more effective and safer therapeutic options.
In Iredell County, where the study is being conducted, COPD is responsible for over 100 deaths annually. Dr. Sever Surdulescu, the Care Access Research Investigator for this study, emphasized the critical need for new therapies to help reduce or prevent these life-threatening exacerbations, offering significant benefits to those with COPD.
The AERIFY-2 study is currently open for enrollment, seeking participants between 40 and 85 diagnosed with moderate-to-severe COPD. Interested individuals are encouraged to visit joincopdstudy.com or contact Care Access, the global research company facilitating the trial, to obtain more information about participating.
Care Access operates in Mooresville coordinating with local community leaders and healthcare providers, aiming to make clinical research more accessible to the local population. They allow residents to engage in clinical trials conveniently close to home, potentially accelerating the development of new medications and broadening participation.
Care Access operates over 150 research sites worldwide and collaborates with 14 of the top 15 biopharmaceutical companies, offering services including site network management, community screenings for enhanced study outreach, staffing, and training programs to support all aspects of clinical study operations.
For further details on active clinical trials and Care Access services or to inquire about enrolling in a study, interested parties can visit www.careaccess.com or email Joseph Ohmedia at media@careaccess.com or call 202-970-6885.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
